Search Tag: RECOVERY trial

Executive Health Management


2020 16 Jun

The U.S. Food and Drug Administration has revoked its emergency use authorisation for chloroquine and hydroxychloroquine as treatments for COVID-19. The U.K. Medicines and Healthcare products Regulatory Agency has followed suit, but Brazil criticised the decision and expanded the drugs’ use.   You might also like: Warnings about Potential...Read more

ICU Management


2021 16 Feb

A large majority of COVID-19 infections are mild or asymptomatic. However, there is a significant portion of individuals who develop severe respiratory illness that requires hospital care, and that could progress to critical illness with hypoxic respiratory failure requiring prolonged ventilatory support. This hypoxic respiratory failure is associated...Read more

ICU Management


2021 14 Dec

The use of aspirin has been proposed as a treatment for COVID-19 because of its anti-thrombotic properties. Thrombosis is a key feature of COVID-19, with 5-30% of hospitalised patients having a major venous thromboembolic event and up to 3% having an arterial thromboembolic event.   The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is...Read more